MedTrace Logo

Efficacy and Safety Prediction of Milrinone or Levosimendan as Initial Inotropic Drug Therapy in Patients With Acute and Advanced Heart Failure With Renal Insufficiency

NCT06205758 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1600

Last updated 2024-01-16

No results posted yet for this study

Summary

1. To evaluate the efficacy and safety of levosimendan and milrinone in the treatment of with acute heart failure with or without renal dysfunction;
2. Predictive modeling of the efficacy and safety of levosimendan and milrinone.

Conditions

Sponsors & Collaborators

  • Qianfoshan Hospital

    collaborator OTHER

  • Yi Han

    lead OTHER

Principal Investigators

  • Yi Han, doctorate · First Affiliated Hospital of Shandon

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-16
Primary Completion
2025-06-01
Completion
2025-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06205758 on ClinicalTrials.gov